SG11201809594WA - Nicotine particles and compositions - Google Patents

Nicotine particles and compositions

Info

Publication number
SG11201809594WA
SG11201809594WA SG11201809594WA SG11201809594WA SG11201809594WA SG 11201809594W A SG11201809594W A SG 11201809594WA SG 11201809594W A SG11201809594W A SG 11201809594WA SG 11201809594W A SG11201809594W A SG 11201809594WA SG 11201809594W A SG11201809594W A SG 11201809594WA
Authority
SG
Singapore
Prior art keywords
international
pct
particles
english
june
Prior art date
Application number
SG11201809594WA
Other languages
English (en)
Inventor
Gerard Zuber
Nicolo Volpe
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of SG11201809594WA publication Critical patent/SG11201809594WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
SG11201809594WA 2016-06-30 2017-06-14 Nicotine particles and compositions SG11201809594WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177163 2016-06-30
PCT/IB2017/053543 WO2018002756A1 (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Publications (1)

Publication Number Publication Date
SG11201809594WA true SG11201809594WA (en) 2018-11-29

Family

ID=56296661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809594WA SG11201809594WA (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Country Status (18)

Country Link
US (2) US20190133940A1 (ru)
EP (1) EP3478264A1 (ru)
JP (2) JP2019524648A (ru)
KR (1) KR102523677B1 (ru)
CN (1) CN109310622A (ru)
AR (1) AR108920A1 (ru)
AU (1) AU2017286864A1 (ru)
BR (1) BR112018076215A2 (ru)
CA (1) CA3023630A1 (ru)
IL (1) IL263355A (ru)
MX (1) MX2018015118A (ru)
PH (1) PH12018502714A1 (ru)
RU (2) RU2021132299A (ru)
SG (1) SG11201809594WA (ru)
TW (1) TW201801716A (ru)
UA (1) UA124535C2 (ru)
WO (1) WO2018002756A1 (ru)
ZA (1) ZA201806949B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021132299A (ru) * 2016-06-30 2021-12-10 Филип Моррис Продактс С.А. Никотиносодержащие частицы и композиции
US20210386665A1 (en) * 2018-10-02 2021-12-16 Meijo University Educational Foundation Inhalation powder medicine, evaluation method thereof, and use thereof
CN114828825A (zh) * 2019-08-30 2022-07-29 塔克索公司 装载的颗粒、其生产方法及其用途
CN110384700A (zh) * 2019-09-03 2019-10-29 云南喜科科技有限公司 一种合成尼古丁的组合物
JP2023502582A (ja) 2019-11-14 2023-01-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 改善されたたばこ風味付き乾燥粉末製剤
CA3164634A1 (en) * 2019-12-19 2021-06-24 Juul Labs, Inc. Organic-based nicotine gel compositions
JPWO2021201258A1 (ru) * 2020-04-01 2021-10-07
EP4208151B1 (en) * 2020-09-03 2024-07-10 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
EP4208153A1 (en) * 2020-09-03 2023-07-12 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
IL300741A (en) * 2020-09-03 2023-04-01 Philip Morris Products Sa Active powder compositions with low hygroscopicity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
IL150461A0 (en) * 1999-12-30 2002-12-01 Chiron Corp Methods for pulmonary delivery of interleukin-2
AU8111301A (en) * 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
BRPI0515932A (pt) * 2004-10-15 2008-08-12 Pfizer Prod Inc composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same
KR102428028B1 (ko) * 2014-04-28 2022-08-03 필립모리스 프로덕츠 에스.에이. 향미를 가진 니코틴 분말 흡입기
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
EP3478265A1 (en) * 2016-06-30 2019-05-08 Philip Morris Products S.a.s. Nicotine particles
RU2021132299A (ru) * 2016-06-30 2021-12-10 Филип Моррис Продактс С.А. Никотиносодержащие частицы и композиции
CA3061895A1 (en) * 2017-06-28 2019-01-03 Philip Morris Products S.A. Container with particles for use with inhaler

Also Published As

Publication number Publication date
KR102523677B1 (ko) 2023-04-20
CN109310622A (zh) 2019-02-05
WO2018002756A1 (en) 2018-01-04
IL263355A (en) 2018-12-31
MX2018015118A (es) 2019-04-15
RU2018145313A3 (ru) 2020-07-30
JP2019524648A (ja) 2019-09-05
AU2017286864A1 (en) 2018-11-15
AR108920A1 (es) 2018-10-10
ZA201806949B (en) 2019-07-31
RU2021132299A (ru) 2021-12-10
PH12018502714A1 (en) 2019-07-29
TW201801716A (zh) 2018-01-16
UA124535C2 (uk) 2021-10-05
US20210361567A1 (en) 2021-11-25
CA3023630A1 (en) 2018-01-04
RU2018145313A (ru) 2020-07-30
BR112018076215A2 (pt) 2019-03-26
US20190133940A1 (en) 2019-05-09
RU2767064C2 (ru) 2022-03-16
KR20190025824A (ko) 2019-03-12
EP3478264A1 (en) 2019-05-08
JP2022071106A (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
SG11201809594WA (en) Nicotine particles and compositions
SG11201909949XA (en) Targeted immunotolerance
SG11201809040YA (en) Hybrid aerosol-generating element and method for manufacturing a hybrid aerosol-generating element
SG11201805072PA (en) Nicotine powder delivery system
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201805204WA (en) Nicotine particle capsule
SG11201809630RA (en) Nicotine particles
SG11201811250TA (en) Nicotine inhaler system
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201907023UA (en) Method of reducing neutropenia
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders